$465 mil­lion set­tle­ment OK’d in EpiPen case

The Commercial Appeal - - Front Page -


My­lan and fed­eral in­ves­ti­ga­tors on Thurs­day fi­nal­ized a $465 mil­lion set­tle­ment of charges that the drug­maker over­charged the gov­ern­ment for the in­jec­tion al­lergy med­i­ca­tion EpiPen.

Re­solv­ing an is­sue that fu­eled na­tion­wide de­bate about soar­ing drug costs, the agree­ment ends an in­ves­ti­ga­tion that found My­lan avoided pay­ing state Med­i­caid pro­grams higher EpiPen re­bates by im­prop­erly clas­si­fy­ing the brand-name drug as a generic med­i­ca­tion.

The drug­maker raised EpiPen prices by roughly 400 per­cent be­tween 2010 and 2016, ac­cord­ing to fed­eral in­ves­ti­ga­tors. EpiPen is a dis­pos­able, pre-filled in­jec­tor that ad­min­is­ters ep­i­neph­rine to coun­ter­act se­vere al­ler­gic re­ac­tions.

“My­lan mis­clas­si­fied its brand-name drug, EpiPen, to profit at the ex­pense of the Med­i­caid pro­gram,” said Wil­liam Wein­reb, the act­ing U.S. at­tor­ney for the Dis­trict of Mas­sachusetts.

My­lan, which dis­closed the set­tle­ment’s size last Oc­to­ber, said the agree­ment re­solves all po­ten­tial Med­i­caid re­bate li­a­bil­ity claims by the fed­eral gov­ern­ment.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.